What is CorMatrix Cardiovascular?
Founded in 2001 and headquartered in Roswell, Georgia, CorMatrix Cardiovascular is at the forefront of developing and commercializing advanced biomaterial devices. The company's proprietary CorMatrix ECM (extracellular matrix) platform technology is designed to harness the body's natural healing capabilities, promoting the remodeling, regrowth, and restoration of damaged heart tissue. This innovative approach facilitates signaling within the body, offers resistance to infection, enables complete tissue remodeling, and provides enduring structural strength. The applications for CorMatrix ECM span critical areas such as pericardial repair and reconstruction, cardiac tissue repair, vascular repair, and even carotid artery repair, positioning the company as a key player in the cardiovascular medical device sector.
How much funding has CorMatrix Cardiovascular raised?
CorMatrix Cardiovascular has raised a total of $24.6M across 1 funding round:
Private Equity
$24.6M
Private Equity (2011): $24.6M, investors not publicly disclosed
What's next for CorMatrix Cardiovascular?
The substantial enterprise-level investment signifies a pivotal moment for CorMatrix Cardiovascular, likely enabling the company to accelerate its research and development initiatives, expand its manufacturing capabilities, and broaden its market penetration. This strategic capital infusion is expected to fuel further clinical validation and commercialization efforts for its ECM platform technology, potentially leading to new product lines or expanded indications for existing devices. The company's focus on regenerative medicine and its proven ability to attract significant investment suggest a strong trajectory for future growth and innovation in addressing unmet needs in cardiovascular repair.
See full CorMatrix Cardiovascular company page
